Generation of dendritic cells for cancer therapy
F.A. Fadeyev¹, A.V. Zamyatin², D.V. Sedneva-Lugovets¹,
I.A. Mikerov², O.V. Gubaeva¹
¹Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation;
²Sverdlovsk Regional Oncological Dispensary, Yekaterinburg, Russian Federation
Abstract. Dendritic cells (DC) are the main population of antigen-presenting cells. The use of ex vivo generated DC for induction of immune response is a promising method of anticancer therapy. The purpose of this study was to assess the efficacy of clinical application of autogenic monocyte-derived dendritic cells for the treatment of patients with cancer after failures of standard therapy. Materials and methods. Monocytes were isolated from patient’s blood. MoDC were differentiated from monocytes in the presence of cytokines. After that their maturation was triggered. Receptors expressed by MoDC were identified by flow cytometry. Results and discussion. MoDC were differentiated from monocytes in the presence of GM-CSF. The generated MoDC had the typical morphology and immunophenotype. The clinical response to MoDC therapy was observed in a third of patients. The temporary partial tumor regression was observed in 13% of patients. The stabilization of patient’s condition for more than 3 months was detected in 20% of cases. Thus, the application of autogenic MoDC for treatment of patients with cancer after failures of standard therapy gave the positive, though limited in time, clinical effect in some cases.
Keywords: dendritic cell vaccine, tumor diseases, clinical efficacy
There is no conflict of interest.
Contact details of the corresponding author:
Fedor A. Fadeyev
fdf79@mail.ru
Received 26.11.2020
For citation:
Fadeyev F.A., Zamyatin A.V., Sedneva-Lugovets D.V., Mikerov I.A., Gubaeva O.V. Generation of dendritic cells for cancer therapy. http://vestnikural.ru/article/1157 [Online] Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2020, Vol. 17, no. 4, pp. 347–353. DOI: 10.22138/2500-0918-2020-17-4-347-353 (In Russ)
REFERENCES
1. Gallo PM., Gallucci S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity // Front Immunol. 2013. V.4. 138. DOI:10.3389/fimmu.2013.00138
2. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases // Cytokine Growth Factor Rev. 2008. V.19(1). P.41-52. DOI:10.1016/j.cytogfr.2007.10.004
3. Gardner A, Ruffell B. Dendritic Cells and Cancer Immunity // Trends Immunol. 2016. V.37(12). P.855-865. DOI:10.1016/j.it.2016.09.006
4. Markov OV, Mironova NL, Vlasov VV, Zenkova MA. Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells // Acta Naturae. 2016. V.8(3). P.17-30.
5. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013. V.39(1). P.38-48. DOI:10.1016/j.immuni.2013.07.004.
6. Hammerstrom A., Cauley D., Atkinson B., Sharma P. et al. Cancer immunotherapy: sipuleucel-T and beyond // Pharmacotherapy. 2011. V. 31(8). P.813-28. DOI: 10.1592/phco.31.8.813
7. Strioga MM, Felzmann T, Powell DJ Jr, Ostapenko V, et al. Therapeutic dendritic cell-based cancer vaccines: the state of the art // Crit Rev Immunol. 2013. V.33(6). P.489-547. doi: 10.1615/critrevimmunol.2013008033.
8. Calmeiro J, Carrascal MA, Tavares AR, et al. Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells // Pharmaceutics. 2020. V.12(2):158. DOI:10.3390/pharmaceutics12020158.
9. Nehaeva, T.L. Optimization of technology and standardization of production of antitumor vaccines based on autologous dendritic cells [Text]: dissertation. … candidate of medical sciences: 14.01.12 / T.L. Nehaeva.– SPb., 2014.– 174 p. (In Russ.)
10. Qu C, Brinck-Jensen NS, Zang M, Chen K. Monocyte-derived dendritic cells: targets as potent antigen-presenting cells for the design of vaccines against infectious diseases // Int J Infect Dis. 2014. V.19. P.1-5. DOI: 10.1016/j.ijid.2013.09.023.
11. Roy K, Bandyopadhyay G, Rakshit S, Ray M, et al. IL-4 alone without the involvement of GM-CSF transforms human peripheral blood monocytes to a CD1a(dim), CD83(+) myeloid dendritic cell subset // Journal of cell science. 2004. V.117. P. 3435-45. DOI:10.1242/jcs.01162.
12. Klein E, Koch S, Borm B, Neumann J, et al. CD83 localization in a recycling compartment of immature human monocyte-derived dendritic cells // International Immunology. 2005. V.17 (4). P. 477–487. DOI:10.1093/intimm/dxh228.
13. Mancino A, Schioppa T, Larghi P, Pasqualini F, et al. Divergent effects of hypoxia on dendritic cell functions // Blood. 2008. V.112 (9). P. 3723–3734. DOI: 10.1182/blood-2008-02-142091.
14. van Gulijk M, Dammeijer F, Aerts JGJV, Vroman H. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy // Front Immunol. 2018 V.9. 2759. DOI:10.3389/fimmu.2018.02759.
Authors
Fedor A. Fadeyev
Institute of Medical Cell Technologies
Candidate of biological sciences, docent, Chief of laboratory
22a Karl Marks str. Yekaterinburg, Russian Federation, 620026
fdf79@mail.ru
Aleksandr V. Zamyatin
Sverdlovsk Regional Oncological Dispensary
Candidate of medical sciences, Oncologist, Chief of the personalized therapy department
29 Sobolev str., Yekaterinburg, Russian Federation, 620036
zamyatin.av@gmail.com
Dayana V. Sedneva-Lugovets
Institute of Medical Cell Technologies
Junior researcher
22a Karl Marks str. Yekaterinburg, Russian Federation, 620026
dyana.lougovets@mail.ru
Ilya A. Mikerov
Sverdlovsk Regional Oncological Dispensary
Oncologist
29 Sobolev str., Yekaterinburg, Russian Federation, 620036
mikerovia@mail.ru
Oksana V. Gubaeva
Institute of Medical Cell Technologies
Technician
22a Karl Marks str. Yekaterinburg, Russian Federation, 620026
gubaeva_oksana@mail.ru